Evidence map›Paper›PMID 35574856›Full record

ArticleCirculation research2022

ATF4 Protects the Heart From Failure by Antagonizing Oxidative Stress.

Xiaoding Wang, Guangyu Zhang, Subhajit Dasgupta, Erica L Niewold, Chao Li, Qinfeng Li, Xiang Luo, Lin Tan, Anwarul Ferdous, Philip L Lorenzi and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 119 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. mJournal of cardiothoracic surgery · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Xiaoding WangDepartment of Cardiology, Renmin Hospital of Wuhan University, Hubei, China (X.W.).
Guangyu ZhangDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Subhajit DasguptaDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Erica L NiewoldDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Chao LiDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-2060-4835
Qinfeng LiDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0003-0582-2102
Xiang LuoDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Lin TanMetabolomics Core Facility, Department of Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston (L.T., P.L.L.).
Anwarul FerdousDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Philip L LorenziMetabolomics Core Facility, Department of Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston (L.T., P.L.L.).ORCID 0000-0003-0385-7774
Beverly A RothermelDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Thomas G GilletteDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.
Christopher M AdamsDivision of Endocrinology, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota (C.A.M.).
Philipp E SchererTouchstone Diabetes Center, Department of Internal Medicine (P.E.S.), University of Texas Southwestern Medical Center, Dallas.
Joseph A HillDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-5379-1614
Zhao V WangDivision of Cardiology, Department of Internal Medicine (X.W., G.Z., S.D., E.L.N., C.L., Q.L., X.L., A.F., B.A.R., T.G.G., J.A.H., Z.V.W.), University of Texas Southwestern Medical Center, Dallas.ORCID 0000-0002-9904-9538
Southwestern Medical Center · USThe University of Texas Southwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · USMayo Clinic · USWuhan University · CN

Funding

Novel Signaling Pathways Underlying Skeletal Muscle AtrophyR01AG060637 · NIA · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2018 to 2022
$2.6M
Cardiomyocyte bromodomain protein 4 (BRD4) in physiology and diseaseR01HL147933 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2020 to 2023
$2.5M
Molecular pathogenesis of skeletal muscle atrophyR01AR071762 · NIAMS · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2017 to 2021
$2.4M
Elevated mitochondrial fusion and function in Down syndrome - Revision - 2R01HD101006 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI ROTHERMEL, BEVERLY A · 2019 to 2022
$2.2M
Molecular Mechanisms of HFpEF-associated Atrial FibrillationR01HL155765 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GILLETTE, THOMAS G, HILL, JOSEPH A · 2021 to 2024
$1.6M
Mechanisms of obesity-dependent alterations in cardiomyocyte metabolismR01HL128215 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2017 to 2020
$1.6M
FoxO-dependent Control of Cardiovascular RemodelingR01HL126012 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2016 to 2019
$1.6M
NHLBI NIH HHS R01 HL126012NHLBI NIH HHS R01 HL128215NHLBI NIH HHS R01 HL147933NHLBI NIH HHS R01 HL155765NIAMS NIH HHS R01 AR071762NIA NIH HHS R01 AG060637NICHD NIH HHS R01 HD101006
6 · The paper itself

Abstract

backgroundCellular redox control is maintained by generation of reactive oxygen/nitrogen species balanced by activation of antioxidative pathways. Disruption of redox balance leads to oxidative stress, a central causative event in numerous diseases including heart failure. Redox control in the heart exposed to hemodynamic stress, however, remains to be fully elucidated.

methodsPressure overload was triggered by transverse aortic constriction in mice. Transcriptomic and metabolomic regulations were evaluated by RNA-sequencing and metabolomics, respectively. Stable isotope tracer labeling experiments were conducted to determine metabolic flux in vitro. Neonatal rat ventricular myocytes and H9c2 cells were used to examine molecular mechanisms.

resultsWe show that production of cardiomyocyte NADPH, a key factor in redox regulation, is decreased in pressure overload-induced heart failure. As a consequence, the level of reduced glutathione is downregulated, a change associated with fibrosis and cardiomyopathy. We report that the pentose phosphate pathway and mitochondrial serine/glycine/folate metabolic signaling, 2 NADPH-generating pathways in the cytosol and mitochondria, respectively, are induced by transverse aortic constriction. We identify ATF4 (activating transcription factor 4) as an upstream transcription factor controlling the expression of multiple enzymes in these 2 pathways. Consistently, joint pathway analysis of transcriptomic and metabolomic data reveal that ATF4 preferably controls oxidative stress and redox-related pathways. Overexpression of ATF4 in neonatal rat ventricular myocytes increases NADPH-producing enzymes' whereas silencing of ATF4 decreases their expression. Further, stable isotope tracer experiments reveal that ATF4 overexpression augments metabolic flux within these 2 pathways. In vivo, cardiomyocyte-specific deletion of ATF4 exacerbates cardiomyopathy in the setting of transverse aortic constriction and accelerates heart failure development, attributable, at least in part, to an inability to increase the expression of NADPH-generating enzymes.

conclusionsOur findings reveal that ATF4 plays a critical role in the heart under conditions of hemodynamic stress by governing both cytosolic and mitochondrial production of NADPH.

Indexed as

Heart FailureOxidative StressActivating Transcription Factor 4AnimalsMiceMyocytes, CardiacNADPRatsReactive Oxygen SpeciesActivating Transcription Factor 4Atf4 protein, ratNADPReactive Oxygen Speciescell deathfibrosisglycineheart failuremetabolomics

Identifiers

PMID35574856
PMCPMC9351829
OpenAlexW4280610542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.